Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) in Q1 CY2025 as sales rose 3% year on year to $2.77 billion. The company ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) in Q1 CY2025 as sales rose 3% year on year to $2.77 billion. The company’s full-year revenue guidance of $11.88 billion at the midpoint came in 0.9 ...

VRTX has recorded a positive one-day return after earnings in 58% of instances. When the return is positive, the median return stands at ...

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2025 investor letter. A ...

Back in 2020, the company announced it would give up the development of VX-814, a potential treatment for alpha-1 antitrypsin ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) was downgraded by Leerink Partnrs from a “strong-buy” rating to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.

Short interest in Vertex Pharmaceuticals Inc (NASDAQ:VRTX) decreased during the last reporting period, falling from 4.37M to 3.78M. This put 1.66% of the company's publicly available shares short.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3% year on year to $2.77 billion. The company’s full-year revenue ...